EPRX
NASD Eupraxia Pharmaceuticals, Inc.$8.49 ↑ +0.19 (+2.23%) Trading Up from the previous close of $8.31
- YTD change
- +12.45%
- vs 20-day SMA
- +4.99%
- vs 200-day SMA
- +16.24%
Price ranges
Price & Performance
+1.69 (+25.64%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 8.9% away from all-time highs of $9.32
- EPRX is up 12% since the beginning of the year
- EPRX is up 44% over the past 12 months
- EPRX is up 31% over the past 1 month
- 12% of all EPRX investors are betting against EPRX
EPRX reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +40.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.21
- Last 5 days
- -1.05%
- vs 8-day SMA
- +1.94%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.
Competitor comparison
No peer group available for this symbol.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.